AL
MRNA icon

Aspiriant LLC’s Moderna MRNA Stock Holding History

Aspiriant LLC’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,492
Closed -$632K – 293
2021
Q4 		$632K Buy
2,492
+39
+2% +$11.4K 0.03% 166
2021
Q3 		$944K Sell
2,453
-906
-27% -$334K 0.06% 123
2021
Q2 		$789K Buy
+3,359
New +$600K 0.04% 130
2020
Q4 		– Sell
-7,500
Closed -$531K – 216
2020
Q3 		$531K Buy
+7,500
New +$523K 0.04% 147

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Aspiriant LLC's MRNA Position: Q1 2022 in Review

Aspiriant LLC sold out of Moderna (MRNA) in Q1 2022, closing a stake of 2,492 shares — an estimated $632K sold.

Aspiriant LLC first reported a position in MRNA in Q3 2020 and held it in 4 quarters. The position peaked at $944K in Q3 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • Aspiriant LLC reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • Aspiriant LLC sold 2,492 Moderna shares in Q1 2022, an estimated $632K.
  • Aspiriant LLC first reported a position in Moderna in Q3 2020 and held it in 4 quarters.
  • Aspiriant LLC's Moderna position peaked at $944K in Q3 2021.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Aspiriant LLC's 13F filing for Q1 2022, filed 6 May 2022.